Адаклин

Quick links to important sections

Адаклин

Treatment option: Zits, Blackheads, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Адаклин

Property Description
Active Ingredient Adapalene
Form Gel or Cream
Pharmacological Class Topical Retinoid (Third-generation)
Origin Synthetic
Route of Administration External (Topical)

What is Адаклин and What Type of Drug Is It?

Адаклин is a medicinal preparation whose active substance is Adapalene, classified under the therapeutic group of Retinoids. Adapalene is a synthetic retinoid derivative developed specifically for topical use. This compound belongs to the third-generation of retinoids, which are chemical substances synthesized to mimic the actions of Vitamin A. The unique design of this molecule—specifically, its structure as a naphthoic acid derivative—imparts advantages such as greater chemical stability and highly selective action when applied to the skin.

Composition and Physical Form of Адаклин

The product Адаклин is an external use preparation supplied as a single-agent topical medicine, containing only the active pharmaceutical ingredient Adapalene. The drug is primarily available in two key dosage forms: a Gel and a Cream. These forms are non-greasy and utilize an inert, water-based vehicle designed to ensure the effective and targeted delivery of the active substance through topical application. The single-agent composition allows the full therapeutic effect to be focused exclusively on the unique properties of the Adapalene molecule itself, contrasting with combination products.

What is the General Purpose of Adapalene?

The general purpose of the active ingredient Adapalene is to normalize cellular processes within the skin that are typically associated with the formation of blemishes, particularly clogged pores. It achieves this through a potent comedolytic effect by modulating follicular epithelial growth and differentiation. The use of topical Adapalene is clinically recognized. By addressing this root cause of cellular dysfunction, Adapalene contributes to improving the overall texture and appearance of the treated skin.

What side effects are possible with Адаклин?

Possible Side Effects and Safety Information

The official safety profile for Adapalene, the active ingredient in Адаклин, is characterized primarily by local cutaneous reactions at the application site, as documented in government regulatory labeling.


Frequency-Classified Adverse Reactions

The majority of documented effects fall under Skin and Subcutaneous Tissue Disorders or General Disorders and Administration Site Conditions.

Classification Examples of Reactions
Common (≥ 1/100 to <1/10) Dry skin, Skin irritation, Erythema (redness), Burning sensation at application site.
Uncommon (≥ 1/1,000 to <1/100) Contact dermatitis, Pruritus (itching), Sunburn, Acne flare-up.
Frequency Unknown Urticaria (hives), Angioedema (swelling), Allergic contact dermatitis.

Time-Related Patterns and Safety Constraints

The most common local reactions (e.g., dryness and irritation) are typically observed most frequently during the first four weeks of treatment and are generally documented to lessen with continued use of the medication. The regulatory information includes reports of rare, serious adverse reactions classified as Immune System Disorders, such as Angioedema.

Safety constraints require patients to minimize exposure to sunlight, including sunlamps, as Adapalene can increase photosensitivity. The preparation must not be applied to areas with cuts, abrasions, eczematous, or sunburnt skin, and contact with the eyes and mucous membranes must be avoided. The safety and effectiveness of the medicine are established for use in patients 12 years of age and older.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance for Adapalene overdose addresses distinct scenarios: excessive topical use and accidental ingestion. Topical application of the product in amounts greater than recommended will not yield faster therapeutic results. Instead, excessive use is formally documented to cause local dermatologic manifestations at the application site, including marked redness (erythema), peeling (scaling/desquamation), and discomfort.


Regulatory Mandates for Urgent Care

Condition Officially Documented Manifestations/Action
Excessive Topical Use Leads to local irritation; often managed by reducing the frequency or temporarily discontinuing use.
Accidental Ingestion (Oral) Poses a systemic risk; chronic ingestion may lead to symptoms associated with Hypervitaminosis A (Vitamin A toxicity).
Required Emergency Action For any acute or significant accidental swallowing of the medication, regulatory guidance requires individuals to seek immediate medical advice and contact emergency services or a Poison Control Center (e.g., 911/1-800-222-1222).

If acute oral ingestion occurs, management is defined as symptomatic and supportive treatment, with consideration for measures like gastric emptying, unless the amount ingested is small. The official labeling does not document a specific antidote for Adapalene overdose. Furthermore, the label requires urgent medical attention for rare but severe allergic reactions, such as angioedema or difficulty breathing.

Therapeutic Uses of Адаклин

Quick Facts

  • Therapeutic Domain: Skin conditions
  • Primary Indication: Management of acne vulgaris
  • Role in Therapy: Helps reduce the occurrence of acne lesions
  • Potential Benefit: Supports clearer skin appearance

Адаклин (Adapalene) is a medication used topically for the management of acne vulgaris, a common skin condition. It is commonly utilized by healthcare providers to address both non-inflammatory lesions (such as blackheads and whiteheads) and inflammatory lesions (such as papules and pustules).

Consistent application of the medication is intended to support the reduction in the number and severity of acne lesions over time. This therapeutic action helps promote an overall smoother skin appearance and assists in maintaining skin clarity, which is a key component of long-term acne control. The use of this agent is recommended in patients 12 years of age and older.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Adapalene

The eligibility profile for topical Adapalene (Адаклин) is strictly defined by regulatory authorities based on patient status and specific dermatological conditions.

Category Official Regulatory Status
Approved Age Group Patients 12 years of age and older.
Pediatric Use Safety and effectiveness have not been established in children mathbfbelow 12 years of age.

Contraindicated Populations:

Adapalene must not be used by individuals with a mathbfknown hypersensitivity to Adapalene or any of the product’s excipients. Its use is mathbfabsolutely contraindicated in women who are mathbfpregnant or mathbfplanning a pregnancy.

Eligibility Restrictions:

The product must not be applied to mathbfbroken skin, including mathbfcuts, mathbfabrasions, mathbfeczematous skin, or mathbfsunburned skin. Use requires patients to mathbfminimize exposure to mathbfsunlight and mathbfartificial UV light. Use during mathbfbreastfeeding is mathbfnot recommended, and the application area mathbfmust be kept away from the infant.

What should I know about interactions with other medicines?

The official regulatory profile for Adaklin (Adapalene) is largely defined by its topical route of administration and resulting minimal systemic exposure. Due to the very low plasma concentrations achieved, no formal drug-drug interaction studies have demonstrated clinically significant systemic pharmacokinetic changes. This classification confirms there is no documented risk of interactions mediated by metabolic enzymes (such as CYP450) or drug transporters when co-administering Adapalene with oral systemic medications. Regulatory labels therefore contain no specific restrictions concerning interactions with food, alcohol, or herbal supplements.

The primary interaction documented is a local pharmacodynamic effect. Concomitant use with other topical preparations is associated with a risk of additive irritation, potentially intensifying dryness, scaling, or redness. This applies to several product categories, including other anti-acne agents and products with strong abrasive or drying properties. Specific interacting substances listed in regulatory documents include preparations containing sulfur, resorcinol, or salicylic acid. To mitigate this officially recognized risk, a timing-based interaction rule is imposed: co-administration with these types of irritants must be avoided. If a combination therapy is necessary, these agents must be applied at separate times of the day to prevent cumulative local effects. This structure confirms that all regulatory constraints are confined to the application site.

Mechanism of Action

The mechanism of Adapalene (Адаклин) is defined by a dual action involving the reversal of cellular abnormalities and the suppression of localized immune signaling. This compound acts exclusively at the site of application by modulating key nuclear receptors and signaling pathways.


Nuclear Receptor Agonism and Cell Normalization

Adapalene functions as a selective agonist for Retinoic Acid Receptors (RARs), primarily RAR-gamma (RAR-gamma) and RAR-beta (RAR-beta), which are abundant in skin cell nuclei. By binding to these receptors, the drug directly modulates gene transcription, which induces the normalization of follicular epithelial cell differentiation. This molecular cascade reverses the abnormal cell clumping (hyperkeratinization), which is the precursor to follicular blockage, yielding a direct comedolytic effect (the physiological clearance and prevention of cell plugs).


Suppression of Innate Inflammatory Signaling

Adapalene exerts a direct anti-inflammatory effect by down-regulating the expression of the immune sensor Toll-Like Receptor 2 (TLR-2) and inhibiting the transcription factor Activator Protein 1 (AP-1). This molecular activity suppresses the release of pro-inflammatory mediators and reduces the migration (chemotaxis) of inflammatory cells, such as neutrophils. The physiological consequence of this targeted suppression is a decrease in localized inflammatory activity within the skin unit.

Dosage and Administration Information

Official Administration Guidelines for Topical Adapalene

The use of Adaklin (Adapalene) is applied topically. It is intended for cutaneous application only and is not for use in the eyes, mouth, or other mucosal areas.


Administration Scope

Parameter Instruction
Route of Administration Topical (External) use only.
Dosing Schedule Apply a thin film (a pea-sized amount for the face) to the entire affected area. Excessive application is not recommended.
Frequency and Timing Once daily application, preferably in the evening or at bedtime.
Preparation Requirements The skin must be gently cleansed with a mild soapless cleanser and then thoroughly dried prior to application.
Age-group Administration Rules Approved for use in patients 12 years of age and older.
Missed-dose Rules If a dose is missed, skip the missed dose and apply the next dose at the regular time in the evening; do not double the amount applied.

Course Duration and Procedural Structure

Topical Adapalene is used as part of a long-term regimen, with initial clinical improvement typically becoming evident after 8 to 12 weeks of continuous use. During the first few weeks, an apparent exacerbation of the acne may occur, which is a documented effect and not a signal to discontinue the application schedule. If local irritation becomes severe, application frequency is sometimes adjusted (e.g., every other day) until symptoms subside. If no therapeutic results are observed after 12 weeks, the patient’s continuing need for the medication should be re-evaluated.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the published research and clinical data that have evaluated the compound. It is descriptive of the studies performed, not interpretive or advisory.


Studies on Blood Glucose Management

Research has investigated the compound's profile. Studies have evaluated whether the compound was associated with changes in blood-sugar levels in type 2 diabetes. Clinical trials evaluated the compound's use in adults. These studies focused on measuring differences in several markers, including:

  • HbA1c: Research has investigated whether use of the compound was associated with long-term changes in HbA1c levels. Research has also examined the potential association between long-term changes in HbA1c and complication risk.
  • Fasting Plasma Glucose (FPG): Studies measured the association of the compound with FPG levels over 12 and 24 weeks.
  • Body Weight: Trials included assessments of whether the compound was associated with differences in body weight during the study period.

Cardiovascular and Renal Outcomes

Studies explored the potential for this compound, when used alongside standard therapy, to be associated with differences in the incidence of serious cardiac events. These trials typically included participants identified as having high cardiovascular risk.

Furthermore, research has examined whether the compound's use was associated with changes in measures of kidney function in individuals with diabetic nephropathy.


Usage and Safety Profile

Information on how the compound was administered in trials is available in the study methodology.

Studies have also evaluated whether the compound was associated with differences in weight management outcomes compared to other orally administered compounds for type 2 diabetes. The findings from these comparative studies were varied across different patient populations.

Specific Study Populations

  • Liver Impairment: Research examined the use of the compound in participants who also had mild liver impairment.
  • Drug-Food Interaction: Studies examining the drug-food interaction have explored whether consuming grapefruit juice had an effect on the compound's metabolism.

Studies have documented the side effects observed in participants. Study reports noted the types of events most commonly reported, which included gastrointestinal disturbances, and studies also evaluated the timeline of symptom resolution following discontinuation of the compound.

Key Studies & References

  1. UK Kidney Association guideline: SGLT2i in adults with kidney disease (Addresses renal and cardiovascular outcomes)
  2. Obesity and Weight Management for Prevention and Treatment of Type 2 Diabetes (Systematic Review and Guideline)
  3. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application (Review of Landmark Trials like CREDENCE, DAPA-CKD, EMPA-KIDNEY)
  4. Grapefruit–medication interactions: Forbidden fruit or avoidable consequences? (Review covering CYP3A4 metabolism interaction)
  5. Sodium-Glucose Transport 2 (SGLT2) Inhibitors - StatPearls (Review covering side effects like infections and adverse events)

Frequently Asked Questions (FAQ)

Common questions about Адаклин (FAQ)


Q: What is the main difference between Адаклин and tretinoin?

Adapalene is a third-generation synthetic retinoid, which gives it a chemical difference from tretinoin, a first-generation retinoid.

Official reviews indicate that Adapalene is chemically more stable and less susceptible to degradation from light or oxygen exposure compared to tretinoin.


Q: Does Адаклин help with blackheads and whiteheads, or just inflamed pimples?

The product is proposed for the cutaneous treatment of acne vulgaris where both comedones (which include blackheads and whiteheads) and inflamed lesions like papules and pustules predominate.

The medication is described as having a dual action that includes both a comedolytic effect (clearing clogged pores) and an anti-inflammatory effect.


Q: Can Адаклин be used long-term?

Adapalene is intended to be used as part of a long-term regimen for the maintenance phase of acne treatment.

Clinical studies have confirmed the safety and tolerability of continuous use for periods of up to 12 months, with adverse events generally described as transient, mild, or moderate.


Q: Is it acceptable to use moisturizer while using Адаклин?

Official product information describes that using moisturizers may be beneficial for patients seeking relief from common local reactions such as dryness or irritation, especially during the initial weeks of treatment.

It is noted that a gentle skin care routine is important during treatment.


Q: How does Адаклин interact with benzoyl peroxide?

Adapalene can be used in treatment plans that include other topical agents, such as benzoyl peroxide. Official guidance, however, cautions against the risk of additive local irritation when combining these products.

Regulatory documents advise that the products are typically applied at separate times of the day to manage this potential side effect.


Q: Why do some people experience dry or peeling skin when using this drug?

Dryness, scaling, and peeling are described as common local cutaneous reactions, often referred to as a retinization effect. This occurs as the skin adjusts to the medication’s action of normalizing cell growth and differentiation.

This reaction is typically observed most often during the first four weeks of use and tends to lessen with continued treatment.


Q: Is there any difference between the gel and cream formulations of Адаклин (if applicable)?

While the core active ingredient is the same, the gel and cream formulations differ in their inactive ingredients and base. The product information indicates the choice of formulation may be guided by skin type.

The gel form is often noted for use with oilier skin, while the cream form may be better tolerated by drier skin types.


Q: Can men and women use Адаклин in the same way?

Yes, regulatory documents provide application and dosing guidelines that are consistent for all patients 12 years of age and older.

There are no separate instructions or dosing schedules based on gender.


Q: If I have sensitive skin, is Адаклин still an option for me?

The labeling addresses the management of irritation, which is a common concern. If irritation, such as redness or dryness, becomes severe, a reduction in application frequency is an option described in regulatory guidance for managing severe symptoms.

Using a moisturizer until symptoms subside is also a described management strategy.


Q: Do I need a prescription to get Адаклин?

The requirement for a prescription depends on the country and the concentration of the active ingredient, Adapalene. In some regions, the 0.1% concentration is approved for over-the-counter (OTC) sale.

Higher concentrations of the drug generally remain prescription-only.


Q: Can Адаклин be used on other parts of the body besides the face?

Yes, Adapalene is approved for cutaneous application only to the affected areas where acne lesions occur.

Regulatory documents specifically mention application to the face, as well as the chest and back.


Q: Does using makeup interfere with the effectiveness of Адаклин?

Regulatory documents advise caution regarding the use of cosmetics that are highly drying or irritating, as these may intensify the local irritation caused by Adapalene.

The use of gentle and non-comedogenic makeup is generally noted as compatible with the treatment regimen.


Q: What precautions related to shaving should be taken while using Адаклин?

Official precautions include avoiding the use of abrasive, highly drying products, or those with large amounts of alcohol, such as certain shaving creams or after-shave lotions.

Hair removal by waxing is also noted in regulatory documents as a procedure to be avoided on skin treated with the medication.


Q: Are there specific instructions in the regulatory documents about what to do if Адаклин gets into the eyes?

The product is not intended for use near the eyes, lips, or mucous membranes.

Official regulatory documents contain instructions that if the product accidentally enters the eyes, the affected area should be washed immediately with warm water.


Q: Is it possible for Адаклин to make the skin more sensitive to cold weather?

Official information notes that skin being treated with Adapalene may be sensitive to weather extremes.

Regulatory documents specifically list wind or cold as potentially irritating factors for patients undergoing treatment.


Q: How is the long-term safety of Адаклин described in medical research?

Clinical trials have evaluated the long-term safety and tolerability of Adapalene for up to 12 months of continuous use. The research indicates that the medication was safe and well-tolerated.

Most adverse effects observed in these long-term studies were mild, moderate, and transient in nature.


Q: Can Адаклин be used in combination with topical antibiotics?

Adapalene can be used as part of a regimen that includes other topical agents, such as antibiotics. Regulatory guidance advises that these different topical products are typically applied at separate times of the day to minimize the risk of cumulative local irritation.


Q: What other names or brand names might Адаклин be known by?

The active ingredient in Adaklin is Adapalene. It is most commonly recognized by the trade name Differin.

Adapalene is also a component in various combination products.


Q: Why is it recommended to wait a certain time after washing the face before applying Адаклин?

Official guidelines require the skin to be gently cleansed and then thoroughly dried prior to application.

This instruction is important because applying the product to damp or wet skin can potentially increase the likelihood of local skin irritation.


Q: Does research indicate that Адаклин's effectiveness varies by skin type?

The product information indicates that while core effectiveness is consistent, the choice of formulation may be guided by skin type.

The gel form is often noted for use with oilier skin, while the cream form may be better tolerated by drier skin types.


Q: What level of severity of acne is Адаклин typically approved for?

Adapalene is officially approved for the cutaneous treatment and maintenance of acne vulgaris.

This generally applies to acne classified as mild-to-moderate in severity, where the lesions primarily consist of comedones, papules, and pustules.


Q: Can Адаклин cause hyperpigmentation or skin darkening?

Official regulatory documents, particularly in the post-marketing experience section, contain reports of changes in the color of the treated skin.

This may include hyperpigmentation or skin darkening in some individuals.


Q: Is it necessary to use sunscreen every day when using Адаклин?

Due to the risk of photosensitivity, regulatory information advises patients to minimize exposure to sunlight, including sunlamps.

The official safety profile notes that the use of sunscreen products and protective clothing is described as recommended whenever sun exposure cannot be completely avoided during treatment.


Q: What is the definition of a 'contraindication' for Адаклин?

A contraindication is a factor or condition that officially makes the use of a drug inadvisable due to the potential for harm. Regulatory documents specify contraindications such as a known hypersensitivity to the ingredients and use during pregnancy or when planning a pregnancy.

How should Адаклин be stored and disposed of?

The storage and disposal of Adaklin (adapalene) must follow official regulatory guidelines to ensure product stability.

Storage Requirements

Storage Component Official Requirement
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Must be protected from freezing.
Container Keep in the original container.
Safety Must be kept out of the reach of children.

The official storage range permits brief temperature excursions between 15 C and 30 C. Freezing is specifically prohibited as it can compromise the product's integrity.

Disposal Instructions

Disposal of any unused or expired product should be managed according to local regulatory requirements or a pharmacist's instruction. The FDA advises that, since Adaklin is not on the flush list, it may be disposed of in household trash after mixing it with an undesirable substance (like dirt or coffee grounds) and placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Адаклин found in:

A-Z Index: